Immunotherapy Drugs Market Share Assessments For The Regional And Country Level Segments

By Author: Pramod Arya
Total Articles: 97
Comment this article

Hospitals and clinics were the key end users in the immunotherapy drugs market, with 81.0% contribution in 2017. The adoption of immunotherapy drugs has been increasing in hospitals and clinics, owing to growing patient population, increasing healthcare expenditure, and rising prevalence of chronic diseases, leading to dominate the end-user segment.

North America was the largest immunotherapy drugs market during the historical period, with more than 50.0% contribution in 2017. This can be attributed to the increasing per capita healthcare spending, surging geriatric population, rising prevalence of chronic diseases, and growing presence of market players in the region. Furthermore, factors such as growing research collaborations, increasing number of research laboratories, and growing direct and indirect investments in research and development (R&D) by pharmaceutical and biotechnology companies will also support the growth of the regional market in the coming years.

Several drugs manufactured by market players for the treatment of chronic diseases are under clinical trials. Thus, increasing use of immunotherapy ...
... drugs to combat the rising prevalence of chronic diseases is an important factor driving the market demand. Moreover, thriving demand and development of mAbs, rise in the implementation of target therapy, and increasing availability of biosimilars are also contributing to the growth of the immunotherapy drugs market.

Download Report Sample at: https://www.psmarketresearch.com/market-analysis/immunotherapy-drugs-market/report-sample

The report provides epidemiology analysis for cancer, autoimmune and inflammatory diseases, and infectious diseases. According to the International Agency for Research on Cancer (IARC) in 2018, 18.1 million people are estimated to be suffering from cancer globally, which is expected to reach 29.5 million by 2040. Another study conducted by the American Medical Association (AMA) between 2005–2015, reported that the incident of cancer cases increased by 33% during this period, of which 16.4% of the cases were due to aging population.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=immunotherapy-drugs-market

The report also covers pricing and reimbursement scenario for immunotherapy drugs on the universal level and for major countries such as the U.S., Belgium, the U.K., France, Italy, Spain, Japan, China, and Australia. For instance, a reimbursement scenario in the U.K. has impacted the cost of the drugs. Keytruda is an immunotherapy drug used for the treatment of melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell cancer (HNSCC), urothelial carcinoma, gastric cancer, and cervical cancer. Keytruda generally costs up to $84,000 to the patients. To reduce the cost of this drug, the National Health Service (NHS) England; a publicly funded national healthcare system, and Merck & Co. Inc. entered into an agreement in June 2018, to reimburse the cost of this drug and provide it for routine use as per the National Institute for Health and Care Excellence (NICE) recommendations. NICE recommends NHS to provide reimbursements for this drug and make it affordable for the patients.

Some of the other leading players operating in the global immunotherapy drugs market are F. Hoffmann-La Roche Ltd., AbbVie Inc., AstraZeneca PLC, Merck & Co. Inc., GlaxoSmithKline plc, Novartis International AG, Johnson & Johnson, Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Sanofi, Medigene AG, C. H. Boehringer Sohn AG & Co. KG, Takeda Pharmaceutical Company Limited, and Celgene Corporation.

Pramod has around 7 years of experience in market research and consulting services for healthcare industry. He holds varied experience in market sizing and forecasting with varied models, competition landscape, consumer behavior analysis, opportunity analysis, product/company benchmarking, data mining and others. He has successfully delivered multiple projects on go-to-market strategies, pricing strategy, price point analysis, Business Expansion, market entry and exit, share analysis and others. Prior to joining P&S Intelligence, he worked with different research companies, including Transparency Market Research and MarketsandMarkets Pvt Ltd. Some of the projects delivered by him include Scar Treatment Market, Skin Replacement and Substitutes Market, and Energy-Based Aesthetic Devices Market.